Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration

Since approximately 30% of patients with Dukes stage B colorectal cancer will experience disease recurrence within five years of primary treatment, current staging of patients with early colorectal cancer apparently fails to adequately predict patient outcome. It has previously been shown that the p...

Full description

Saved in:
Bibliographic Details
Published in:The International journal of biological markers 2005-04, Vol.20 (2), p.93-102
Main Authors: Riisbro, R, Christensen, I J, Nielsen, H J, Brunner, N, Nilbert, M, Fernebro, E
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c208t-9e27549fdca84db1ac12cedce8955da5ad3a19c858e06f487aa1870ebdf4fec03
cites
container_end_page 102
container_issue 2
container_start_page 93
container_title The International journal of biological markers
container_volume 20
creator Riisbro, R
Christensen, I J
Nielsen, H J
Brunner, N
Nilbert, M
Fernebro, E
description Since approximately 30% of patients with Dukes stage B colorectal cancer will experience disease recurrence within five years of primary treatment, current staging of patients with early colorectal cancer apparently fails to adequately predict patient outcome. It has previously been shown that the preoperative plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) is associated with the survival of patients with early colo-rectal cancer. In this study we sought to confirm the independent prognostic value of suPAR in rectal cancer. suPAR was retrospectively determined by two different versions of a suPAR ELISA in preoperatively collected plasma samples from a Swedish (n=354) and a Danish (n=255) cohort of rectal cancer patients. In both cohorts the suPAR concentration was significantly higher in Dukes stage D patients than in Dukes stage A-C patients (p
doi_str_mv 10.5301/JBM.2008.5473
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1869092253</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1869092253</sourcerecordid><originalsourceid>FETCH-LOGICAL-c208t-9e27549fdca84db1ac12cedce8955da5ad3a19c858e06f487aa1870ebdf4fec03</originalsourceid><addsrcrecordid>eNo9kbFOwzAQhi0EglIYWZFHlhTbiRNnbKtSQEVFCObo4lxQILWDnSDxSjwljihMts6f_7vTR8gFZzMZM359v3iYCcbUTCZZfEAmPBNJlIbCIZmwOI-jlEt5Qk69f2NMcJalx-REKMEynogJ-X50aDt00DefSLsW_A6ot-1QtkgHZ98bA37_0Bj7ioaCDiz01lGHGrvxAp4C7Zx9Ndb3jaY7cO_oaGNGpIeWajA6FLrQBk3vZ3Ru6Gr79LyMnv4zTEUXjd1_XTs7dFTbtoXSjtNZc0aOamg9nu_PKXm5WT0vb6PNdn23nG8iLZjqoxxFJpO8rjSopCo5aC40VhpVLmUFEqoYeK6VVMjSOlEZAFcZw7Kqkxo1i6fk6jc3LPQxoO-LXeM1hkkM2sEXXKU5y4WQcUCjX1Q7673DuuhcEzb4KjgrRj1F0FOMeopRT-Av99FDucPqn_7zEf8AFneP0g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1869092253</pqid></control><display><type>article</type><title>Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration</title><source>Sage Journals GOLD Open Access 2024</source><creator>Riisbro, R ; Christensen, I J ; Nielsen, H J ; Brunner, N ; Nilbert, M ; Fernebro, E</creator><creatorcontrib>Riisbro, R ; Christensen, I J ; Nielsen, H J ; Brunner, N ; Nilbert, M ; Fernebro, E</creatorcontrib><description>Since approximately 30% of patients with Dukes stage B colorectal cancer will experience disease recurrence within five years of primary treatment, current staging of patients with early colorectal cancer apparently fails to adequately predict patient outcome. It has previously been shown that the preoperative plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) is associated with the survival of patients with early colo-rectal cancer. In this study we sought to confirm the independent prognostic value of suPAR in rectal cancer. suPAR was retrospectively determined by two different versions of a suPAR ELISA in preoperatively collected plasma samples from a Swedish (n=354) and a Danish (n=255) cohort of rectal cancer patients. In both cohorts the suPAR concentration was significantly higher in Dukes stage D patients than in Dukes stage A-C patients (p&lt;0.0001). Among Dukes stage A-C patients, no differences in median suPAR values were seen. In univariate analysis, continuous suPAR was found to be associated with survival (p&lt;0.0001 in both cohorts). Of particular interest was that similar results were obtained for Dukes stage A and B patients when analyzed separately. In multivariate analysis, continuous suPAR was found in both cohorts to be independent of Dukes stage. This study confirms that the preoperative concentration of plasma suPAR contains independent prognostic information on patients with rectal cancer. This result was independent of the two different versions of an in-house suPAR ELISA used to perform the analyses. The next step in the evaluation of suPAR as a prognostic parameter in rectal cancer will be to launch an appropriately dimensioned prospective study where the benefit of applying preoperative plasma suPAR measurement to clinical decision-making regarding adjuvant therapy is assessed. (Int J Biol Markers 2005; 20: 93-102).</description><identifier>ISSN: 0393-6155</identifier><identifier>EISSN: 1724-6008</identifier><identifier>DOI: 10.5301/JBM.2008.5473</identifier><identifier>PMID: 28207142</identifier><language>eng</language><publisher>United States</publisher><ispartof>The International journal of biological markers, 2005-04, Vol.20 (2), p.93-102</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c208t-9e27549fdca84db1ac12cedce8955da5ad3a19c858e06f487aa1870ebdf4fec03</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28207142$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Riisbro, R</creatorcontrib><creatorcontrib>Christensen, I J</creatorcontrib><creatorcontrib>Nielsen, H J</creatorcontrib><creatorcontrib>Brunner, N</creatorcontrib><creatorcontrib>Nilbert, M</creatorcontrib><creatorcontrib>Fernebro, E</creatorcontrib><title>Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration</title><title>The International journal of biological markers</title><addtitle>Int J Biol Markers</addtitle><description>Since approximately 30% of patients with Dukes stage B colorectal cancer will experience disease recurrence within five years of primary treatment, current staging of patients with early colorectal cancer apparently fails to adequately predict patient outcome. It has previously been shown that the preoperative plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) is associated with the survival of patients with early colo-rectal cancer. In this study we sought to confirm the independent prognostic value of suPAR in rectal cancer. suPAR was retrospectively determined by two different versions of a suPAR ELISA in preoperatively collected plasma samples from a Swedish (n=354) and a Danish (n=255) cohort of rectal cancer patients. In both cohorts the suPAR concentration was significantly higher in Dukes stage D patients than in Dukes stage A-C patients (p&lt;0.0001). Among Dukes stage A-C patients, no differences in median suPAR values were seen. In univariate analysis, continuous suPAR was found to be associated with survival (p&lt;0.0001 in both cohorts). Of particular interest was that similar results were obtained for Dukes stage A and B patients when analyzed separately. In multivariate analysis, continuous suPAR was found in both cohorts to be independent of Dukes stage. This study confirms that the preoperative concentration of plasma suPAR contains independent prognostic information on patients with rectal cancer. This result was independent of the two different versions of an in-house suPAR ELISA used to perform the analyses. The next step in the evaluation of suPAR as a prognostic parameter in rectal cancer will be to launch an appropriately dimensioned prospective study where the benefit of applying preoperative plasma suPAR measurement to clinical decision-making regarding adjuvant therapy is assessed. (Int J Biol Markers 2005; 20: 93-102).</description><issn>0393-6155</issn><issn>1724-6008</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNo9kbFOwzAQhi0EglIYWZFHlhTbiRNnbKtSQEVFCObo4lxQILWDnSDxSjwljihMts6f_7vTR8gFZzMZM359v3iYCcbUTCZZfEAmPBNJlIbCIZmwOI-jlEt5Qk69f2NMcJalx-REKMEynogJ-X50aDt00DefSLsW_A6ot-1QtkgHZ98bA37_0Bj7ioaCDiz01lGHGrvxAp4C7Zx9Ndb3jaY7cO_oaGNGpIeWajA6FLrQBk3vZ3Ru6Gr79LyMnv4zTEUXjd1_XTs7dFTbtoXSjtNZc0aOamg9nu_PKXm5WT0vb6PNdn23nG8iLZjqoxxFJpO8rjSopCo5aC40VhpVLmUFEqoYeK6VVMjSOlEZAFcZw7Kqkxo1i6fk6jc3LPQxoO-LXeM1hkkM2sEXXKU5y4WQcUCjX1Q7673DuuhcEzb4KjgrRj1F0FOMeopRT-Av99FDucPqn_7zEf8AFneP0g</recordid><startdate>200504</startdate><enddate>200504</enddate><creator>Riisbro, R</creator><creator>Christensen, I J</creator><creator>Nielsen, H J</creator><creator>Brunner, N</creator><creator>Nilbert, M</creator><creator>Fernebro, E</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200504</creationdate><title>Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration</title><author>Riisbro, R ; Christensen, I J ; Nielsen, H J ; Brunner, N ; Nilbert, M ; Fernebro, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c208t-9e27549fdca84db1ac12cedce8955da5ad3a19c858e06f487aa1870ebdf4fec03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Riisbro, R</creatorcontrib><creatorcontrib>Christensen, I J</creatorcontrib><creatorcontrib>Nielsen, H J</creatorcontrib><creatorcontrib>Brunner, N</creatorcontrib><creatorcontrib>Nilbert, M</creatorcontrib><creatorcontrib>Fernebro, E</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The International journal of biological markers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Riisbro, R</au><au>Christensen, I J</au><au>Nielsen, H J</au><au>Brunner, N</au><au>Nilbert, M</au><au>Fernebro, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration</atitle><jtitle>The International journal of biological markers</jtitle><addtitle>Int J Biol Markers</addtitle><date>2005-04</date><risdate>2005</risdate><volume>20</volume><issue>2</issue><spage>93</spage><epage>102</epage><pages>93-102</pages><issn>0393-6155</issn><eissn>1724-6008</eissn><abstract>Since approximately 30% of patients with Dukes stage B colorectal cancer will experience disease recurrence within five years of primary treatment, current staging of patients with early colorectal cancer apparently fails to adequately predict patient outcome. It has previously been shown that the preoperative plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) is associated with the survival of patients with early colo-rectal cancer. In this study we sought to confirm the independent prognostic value of suPAR in rectal cancer. suPAR was retrospectively determined by two different versions of a suPAR ELISA in preoperatively collected plasma samples from a Swedish (n=354) and a Danish (n=255) cohort of rectal cancer patients. In both cohorts the suPAR concentration was significantly higher in Dukes stage D patients than in Dukes stage A-C patients (p&lt;0.0001). Among Dukes stage A-C patients, no differences in median suPAR values were seen. In univariate analysis, continuous suPAR was found to be associated with survival (p&lt;0.0001 in both cohorts). Of particular interest was that similar results were obtained for Dukes stage A and B patients when analyzed separately. In multivariate analysis, continuous suPAR was found in both cohorts to be independent of Dukes stage. This study confirms that the preoperative concentration of plasma suPAR contains independent prognostic information on patients with rectal cancer. This result was independent of the two different versions of an in-house suPAR ELISA used to perform the analyses. The next step in the evaluation of suPAR as a prognostic parameter in rectal cancer will be to launch an appropriately dimensioned prospective study where the benefit of applying preoperative plasma suPAR measurement to clinical decision-making regarding adjuvant therapy is assessed. (Int J Biol Markers 2005; 20: 93-102).</abstract><cop>United States</cop><pmid>28207142</pmid><doi>10.5301/JBM.2008.5473</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0393-6155
ispartof The International journal of biological markers, 2005-04, Vol.20 (2), p.93-102
issn 0393-6155
1724-6008
language eng
recordid cdi_proquest_miscellaneous_1869092253
source Sage Journals GOLD Open Access 2024
title Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T23%3A28%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preoperative%20plasma%20soluble%20urokinase%20plasminogen%20activator%20receptor%20as%20a%20prognostic%20marker%20in%20rectal%20cancer%20patients.%20An%20EORTC-Receptor%20and%20Biomarker%20Group%20collaboration&rft.jtitle=The%20International%20journal%20of%20biological%20markers&rft.au=Riisbro,%20R&rft.date=2005-04&rft.volume=20&rft.issue=2&rft.spage=93&rft.epage=102&rft.pages=93-102&rft.issn=0393-6155&rft.eissn=1724-6008&rft_id=info:doi/10.5301/JBM.2008.5473&rft_dat=%3Cproquest_cross%3E1869092253%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c208t-9e27549fdca84db1ac12cedce8955da5ad3a19c858e06f487aa1870ebdf4fec03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1869092253&rft_id=info:pmid/28207142&rfr_iscdi=true